On Friday, Shares of Mastercard Inc (NYSE:MA), added 0.11% and closed at $104.62 in the last trading session. The last trading range of the stock ranges between $103.66 and $105.06. MasterCard Incorporated, a technology company, provides transaction processing and other payment-related products and services in the United States and internationally. It facilitates the processing of payment transactions, counting authorization, clearing, and settlement, in addition to delivers related products and services. The company also offers value-added services, such as loyalty and reward programs, and information and consulting services. In addition, it provides cross-border and domestic processing services; and issuer and acquirer processing solutions, and payment and mobile gateways. Further, the company offers various payment products and solutions for cardholders, merchants, financial institutions, and governments; programs that facilitate issuers to provide consumers with cards to defer payments; payment products and solutions that allow its customers to access funds in deposit and other accounts; prepaid payment programs and administration services; and commercial payment products and solutions.
Keryx Biopharmaceuticals (NASDAQ:KERX), jumped 13.70% and closed at $6.39 in the last trading session. The last trading range of the stock ranges between $5.57 and $6.40. The company’s Market capitalization is $769.38 million with the total Outstanding Shares of 105.06 million. Keryx Biopharmaceuticals, Inc. (KERX), a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, recently declared that the U.S. Food and Drug Administration (FDA) has approved its application for a second drug product contract manufacturer. Patheon Manufacturing Services LLC of Greenville, North Carolina, a leading global provider of pharmaceutical manufacturing services, is now an FDA approved drug product manufacturer of Auryxia®. With FDA approval of this manufacturer, the company has rebuilt supply and will promptly make Auryxia available to wholesalers.
“We are happy with recently’s approval, as it expands our manufacturing capabilities and capacity,” said Greg Madison, president and chief executive officer of Keryx Biopharmaceuticals. “Getting a second drug product manufacturer approved was an important step to ensuring long-term supply of Auryxia is consistently available to patients.”